Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Drug-Eluting Stents70 Restenotic Cases From a Cohort of 718 Patients: FAILS (Failure in Left Main Study)
Imad Sheiban, MD*,
Dario Sillano, MD*,
Giuseppe Biondi-Zoccai, MD*,*,
Alaide Chieffo, MD ,
Antonio Colombo, MD ,
Sabine Vecchio, MD ,
Massimo Margheri, MD ,
Julian P. Gunn, MD ,
Tushar Raina, MD ,
Francesco Liistro, MD||,
Leonardo Bolognese, MD||,
Michael S. Lee, MD¶,
Jonathan Tobis, MD¶ and
Claudio Moretti, MD, PhD*
* Division of Cardiology, University of Turin, Turin, Italy
St. Raffaele Hospital and Centro Cuore Columbus, Milan, Italy
Division of Cardiology, Ravenna Hospital, Ravenna, Italy
Division of Cardiology, University of Sheffield, Sheffield, United Kingdom
|| Division of Cardiology, San Donato Hospital, Arezzo, Italy
¶ Division of Cardiology, UCLA Medical Center, Los Angeles, California

View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Study Profile
angio = angiographic; CABG = coronary artery bypass grafting; DES = drug-eluting stent(s); PCI = percutaneous coronary intervention; ULM = unprotected left main.
|
|
|